Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety and immunogenicity study of Agrippal S1 2012-2013 influenza vaccine in adults and elderly subjects
2012-000063-24Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of influenza vaccine, inactivated, surface antigen in influenza, sponsored by Novartis. Primary endpoints: Safety after single intramuscular vaccination, Immunogenicity by SRH in non-elderly adults and 2 more. Started Mar 2012; status: terminated.
02
Drugs
influenza vaccine, inactivated, surface antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2012-000063-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000063-24.